Ignite Creation Date:
2024-05-06 @ 2:38 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04381741
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-02-06
First Post:
2020-05-06
Brief Title:
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CICPD
Brief Summary:
Diffuse large B-cell lymphoma DLBCL is the most common non-Hodgkins lymphoma accounting for 35 of lymphoma Chimeric antigen receptor T cell CAR-T therapy is a new method to treat DLBCL KTE-C19 published in the New England Medical Journal in December 2017 was used to treat relapsed and refractory B-cell lymphoma One year of treatment for 111 patients the total response rate was 82 and the complete remission rate was 54 However a large number of clinical studies have shown that about 20 of patients with B-ALL and 50 of patients with B-NHL cannot achieve complete remission CR after CD19-CAR-T treatment Targeting tumor microenvironment is an important new method to overcome the drug resistance of CAR-T cells In this study IL-7 and CCL19 were connected on the basis of traditional second generation CD19 CAR-T cells to construct novel fourth generation CAR-T cells which can promote the infiltration accumulation and survival of CAR-T cells in lymphoma tissue and further enhance the anti-tumor effect of traditional CAR-T cells At the same time combined with four generations of CAR-T cells and PD1 monoclonal antibody PD1 PDL1 signal pathway was blocked anti-tumor effect of CAR-T was improved and immune response and long-term remission rate of DLBCL were improved
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None